Oruka Therapeutics (ORKA) Other Gross PP&E Adjustments (2011 - 2026)
Oruka Therapeutics' quarterly Other Gross PP&E Adjustments came in at -$2.5 million in Q1 2026, down 89.24% year-on-year from -$22.9 million in Q1 2025, and up 11.15% quarter-over-quarter from -$2.8 million in Q4 2025.
Oruka Therapeutics has reported Other Gross PP&E Adjustments for 16 years, with the latest figure at -$2.5 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 89.24% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 89.24% YoY), and the FY2025 full-year result was -$2.8 million, up 29.65% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$2.5 million, up from -$2.8 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was $214000.0 in Q2 2024, with the low at -$3.9 million in Q4 2024.
- Average Other Gross PP&E Adjustments over 5 years is -$1.0 million, with a median of -$257000.0 recorded in 2023.
- Peak annual rise in Other Gross PP&E Adjustments reached 434.38% in 2024, while the deepest fall reached 2905.26% in 2024.
- Tracing ORKA's Other Gross PP&E Adjustments over 5 years: stood at -$319000.0 in 2022, then grew by 19.44% to -$257000.0 in 2023, then tumbled by 1432.68% to -$3.9 million in 2024, then increased by 29.65% to -$2.8 million in 2025, then climbed by 11.15% to -$2.5 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$2.5 million (Q1 2026), -$2.8 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | -2.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.46 Mn |
| Mar 31, 2026 | -2.46 Mn |
| Dec 31, 2025 | -2.77 Mn |
| Dec 31, 2025 | -2.77 Mn |
| Sep 30, 2025 | -2.98 Mn |
| Sep 30, 2025 | -2.98 Mn |
| Jun 30, 2025 | -2.21 Mn |
| Jun 30, 2025 | -2.21 Mn |
| Mar 31, 2025 | -1.30 Mn |
| Mar 31, 2025 | -1.30 Mn |
| Dec 31, 2024 | -3.94 Mn |
| Dec 31, 2024 | -3.94 Mn |
| Sep 30, 2024 | -1.14 Mn |
| Sep 30, 2024 | -1.14 Mn |
| Jun 30, 2024 | 214,000.00 |
| Jun 30, 2024 | 214,000.00 |
| Mar 31, 2024 | 205,000.00 |
| Mar 31, 2024 | 205,000.00 |
| Dec 31, 2023 | -257,000.00 |
| Dec 31, 2023 | -257,000.00 |
| Sep 30, 2023 | -38,000.00 |
| Sep 30, 2023 | -38,000.00 |
| Jun 30, 2023 | -64,000.00 |
| Jun 30, 2023 | -64,000.00 |
| Mar 31, 2023 | -89,000.00 |
| Mar 31, 2023 | -89,000.00 |
| Dec 31, 2022 | -319,000.00 |
| Dec 31, 2022 | -319,000.00 |
| Sep 30, 2022 | -136,000.00 |
| Sep 30, 2022 | -136,000.00 |
| Jun 30, 2022 | -150,000.00 |
| Jun 30, 2022 | -150,000.00 |
| Mar 31, 2022 | -173,000.00 |
| Mar 31, 2022 | -173,000.00 |
| Dec 31, 2021 | -346,000.00 |
| Dec 31, 2021 | -346,000.00 |
| Sep 30, 2021 | -195,000.00 |
| Sep 30, 2021 | -195,000.00 |
| Jun 30, 2021 | -225,000.00 |
| Jun 30, 2021 | -225,000.00 |
| Mar 31, 2021 | -134,000.00 |
| Mar 31, 2021 | -134,000.00 |
| Dec 31, 2020 | -273,000.00 |
| Dec 31, 2020 | -273,000.00 |
| Sep 30, 2020 | 270,000.00 |
| Sep 30, 2020 | 270,000.00 |
| Jun 30, 2020 | 332,000.00 |
| Jun 30, 2020 | 332,000.00 |
| Mar 31, 2020 | 331,000.00 |
| Mar 31, 2020 | 331,000.00 |
| Dec 31, 2019 | 236,000.00 |
| Dec 31, 2019 | 236,000.00 |
| Sep 30, 2019 | 380,000.00 |
| Sep 30, 2019 | 380,000.00 |
| Jun 30, 2019 | 361,000.00 |
| Jun 30, 2019 | 361,000.00 |
| Mar 31, 2019 | 354,000.00 |
| Mar 31, 2019 | 354,000.00 |
| Dec 31, 2018 | 271,000.00 |
| Dec 31, 2018 | 271,000.00 |
| Sep 30, 2018 | 432,000.00 |
| Sep 30, 2018 | 432,000.00 |
| Jun 30, 2018 | 431,000.00 |
| Jun 30, 2018 | 431,000.00 |
| Mar 31, 2018 | 444,000.00 |
| Mar 31, 2018 | 444,000.00 |
| Dec 31, 2017 | 295,000.00 |
| Dec 31, 2017 | 295,000.00 |
| Sep 30, 2017 | 451,000.00 |
| Sep 30, 2017 | 451,000.00 |
| Jun 30, 2017 | 450,000.00 |
| Jun 30, 2017 | 450,000.00 |
| Mar 31, 2017 | 453,000.00 |
| Mar 31, 2017 | 453,000.00 |
| Dec 31, 2016 | 260,000.00 |
| Dec 31, 2016 | 260,000.00 |
| Sep 30, 2016 | 449,000.00 |
| Sep 30, 2016 | 449,000.00 |
| Jun 30, 2016 | 448,000.00 |
| Jun 30, 2016 | 448,000.00 |
| Mar 31, 2016 | 405,000.00 |
| Mar 31, 2016 | 405,000.00 |
| Dec 31, 2015 | 253,000.00 |
| Dec 31, 2015 | 253,000.00 |
| Sep 30, 2015 | 415,000.00 |
| Sep 30, 2015 | 415,000.00 |
| Jun 30, 2015 | 425,000.00 |
| Jun 30, 2015 | 425,000.00 |
| Mar 31, 2015 | 420,000.00 |
| Mar 31, 2015 | 420,000.00 |
| Dec 31, 2014 | 260,000.00 |
| Dec 31, 2014 | 260,000.00 |
| Sep 30, 2014 | 404,000.00 |
| Sep 30, 2014 | 404,000.00 |
| Jun 30, 2014 | 429,000.00 |
| Jun 30, 2014 | 429,000.00 |
| Mar 31, 2014 | 514,000.00 |
| Mar 31, 2014 | 514,000.00 |
| Dec 31, 2013 | 60,000.00 |
| Dec 31, 2013 | 60,000.00 |
| Sep 30, 2013 | 509,000.00 |
| Sep 30, 2013 | 509,000.00 |
| Jun 30, 2013 | 517,000.00 |
| Jun 30, 2013 | 517,000.00 |
| Mar 31, 2013 | 508,000.00 |
| Mar 31, 2013 | 508,000.00 |
| Dec 31, 2012 | 533,000.00 |
| Dec 31, 2012 | 533,000.00 |
| Sep 30, 2012 | 514,000.00 |
| Sep 30, 2012 | 514,000.00 |
| Jun 30, 2012 | 494,000.00 |
| Jun 30, 2012 | 494,000.00 |
| Dec 31, 2011 | 533,000.00 |
| Dec 31, 2011 | 533,000.00 |